과제정보
본 연구는 국민건강보험 일산병원의 연구비 지원으로 이루어졌음(NHIMC2020CR078).
참고문헌
- Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2004;161(2 Suppl):1-56. https://doi.org/10.1176/appi.ajp.161.1.1
- Lally J, Gaughran F. Treatment resistant schizophrenia-review and a call to action. Ir J Psychol Med 2019;36:279-291. https://doi.org/10.1017/ipm.2018.47
- Howes OD, McCutcheon R, Agid O, De Bartolomeis A, Van Beveren NJ, Birnbaum ML, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017;174:216-229. https://doi.org/10.1176/appi.ajp.2016.16050503
- Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry 2017;17:1-14. https://doi.org/10.1186/s12888-016-1163-4
- National Collaborating Centre for Mental Health (UK). Psychosis and schizophrenia in adults: treatment and management. London: National Institute for Health and Care Excellence (UK);2014.
- Lee K. Treatment-Resistant Schizophrenia: terminology and Clinical Features. Korean J Schizophr Res 2020;23:45-50. https://doi.org/10.16946/kjsr.2020.23.2.45
- Kinon BJ. The group of treatment resistant schizophrenias. Heterogeneity in treatment resistant schizophrenia (TRS). Front Psychiatry 2019;9:757. https://doi.org/10.3389/fpsyt.2018.00757
- Meltzer HY, Rabinowitz J, Lee MA, Cola PA, Ranjan R, Findling RL, et al. Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. Am J Psychiatry 1997;154:475-482. https://doi.org/10.1176/ajp.154.4.475
- Schennach R, Riedel M, Musil R, Moller HJ. Treatment response in first-episode schizophrenia. Clin Psychopharmacol Neurosci 2012;10:78. https://doi.org/10.9758/cpn.2012.10.2.78
- Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796. https://doi.org/10.1001/archpsyc.1988.01800330013001
- Kane JM, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64:5-19. https://doi.org/10.4088/JCP.v64n0301
- Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, et al. A randomized, double-blind comparison of clozapine and highdose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2008;69:274-285. https://doi.org/10.4088/JCP.v69n0214
- Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-962. https://doi.org/10.1016/S0140-6736(13)60733-3
- Wheeler A, Humberstone V, Robinson G. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? J Psychopharmacol 2009;23:957-965. https://doi.org/10.1177/0269881108093588
- Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13:318-378. https://doi.org/10.3109/15622975.2012.696143
- Norman R, Lecomte T, Addington D, Anderson E. Canadian treatment guidelines on psychosocial treatment of schizophrenia in adults. Can J Psychiatry 2017;62:617-623. https://doi.org/10.1177/0706743717719894
- Taylor DM, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003;64:30-34. https://doi.org/10.4088/JCP.v64n0107
- Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of anti-psychotic treatment prior to clozapine initiation. Br J Psychiatry 2012;201:481-485. https://doi.org/10.1192/bjp.bp.111.105833
- Kim SH. Current status of clozapine for treatment-resistant schizophrenia. Korean J Schizophr Res 2021;24:1-7. https://doi.org/10.16946/kjsr.2021.24.1.1
- Wheeler AJ, Feetam CL, Harrison J. Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom. Clin Drug Investig 2014;34:203-211. https://doi.org/10.1007/s40261-013-0166-x
- Kang SH, Lee HW. Prescribing pattern of clozapine and clinical factors associated with discontinuation of clozapine. Korean J Schizophr Res 2019;22:1-7. https://doi.org/10.16946/kjsr.2019.22.1.1
- Okhuijsen-Pfeifer C, Sterk A, Horn I, Terstappen J, Kahn R, Luykx J. Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: a systematic review and meta-analysis. Neurosci Biobehav Rev 2020;111:246-252. https://doi.org/10.1016/j.neubiorev.2020.01.017
- Griffiths K, Millgate E, Egerton A, MacCabe JH. Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis. Psychol Med 2021;51:376-386. https://doi.org/10.1017/S0033291721000246
- Altamura A, Bassetti R, Sassella F, Salvadori D, Mundo E. Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study. Schizophr Res 2001;52:29-36. https://doi.org/10.1016/S0920-9964(00)00187-0
- Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005;162:1785-1804. https://doi.org/10.1176/appi.ajp.162.10.1785
- Shah P, Iwata Y, Plitman E, Brown EE, Caravaggio F, Kim J, et al. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review. Psychiatry Res 2018;268:114-122. https://doi.org/10.1016/j.psychres.2018.06.070
- Shah P, Iwata Y, Brown EE, Kim J, Sanches M, Takeuchi H, et al. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. Eur Arch Psychiatry Clin Neurosci 2020;270:11-22. https://doi.org/10.1007/s00406-019-01053-6
- Ucok A, Cikrikcili U, Karabulut S, Salaj A, Ozturk M, Tabak O, et al. Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. Int Clin Psychopharmacol 2015;30:290-295. https://doi.org/10.1097/YIC.0000000000000086
- Lee JS, Yun JY, Kang SH, Lee SJ, Choi JH, Nam B, et al. Korean Medication Algorithm for Schizophrenia 2019, second revision: treatment of psychotic symptoms. Clin Psychopharmacol Neurosci 2020;18:386-394. https://doi.org/10.9758/cpn.2020.18.3.386
- Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261. https://doi.org/10.1093/schbul/13.2.261
- Guy W. ECDEU assessment manual for psychopharmacology. Rockville: U. S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs;1976.
- Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006;31:2318-2325. https://doi.org/10.1038/sj.npp.1301147
- Yoshimura B, Yada Y, So R, Takaki M, Yamada N. The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res 2017;250:65-70. https://doi.org/10.1016/j.psychres.2017.01.064
- Thien K, O'Donoghue B. Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: a literature review. Early Interv Psychiatry 2019;13:18-23. https://doi.org/10.1111/eip.12683
- Cho JW, Kim WH, Shin JH, Kim JH, Lee JS, Bae JN, et al. Reason for clozapine discontinuation. Korean J Schizophr Res 2016;19:17-24. https://doi.org/10.16946/kjsr.2016.19.1.17
- Hayhurst KP, Brown P, Lewis SW. Postcode prescribing for schizophrenia. Br J Psychiatry 2003;182:281-283. https://doi.org/10.1192/bjp.182.4.281
- Cirulli G. Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units. Psychiatr Bull 2005;29:377-380. https://doi.org/10.1192/pb.29.10.377
- Farooq S, Choudry A, Cohen D, Naeem F, Ayub M. Barriers to using clozapine in treatment-resistant schizophrenia: systematic review. B J Psych Bull 2019;43:8-16.
- Gee S, Vergunst F, Howes O, Taylor D. Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 2014;130:16-24. https://doi.org/10.1111/acps.12193
- Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003;15:33-48. https://doi.org/10.1023/A:1023228626309
- Laker M, Duffett R, Cookson J. Long-term outcome with clozapine: comparison of patients continuing and discontinuing treatment. Int Clin Psychopharmacol 1998;13:75-78. https://doi.org/10.1097/00004850-199803000-00003
- Young CR, Bowers Jr MB, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998;24:381. https://doi.org/10.1093/oxfordjournals.schbul.a033333
- Jeon YH, Jung MY. The determinants of the length of stay in hospital for schizophrenic patients: using from the Health Insurance Claim Data of inpatients. J Digit Converg 2020;18:257-263.
- Conley RR, Carpenter Jr WT, Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry 1997;154:1243-1247. https://doi.org/10.1176/ajp.154.9.1243